What is the primary driver of the revenue growth in the first half of 2002?

The primary driver of revenue growth was the strong performance of the anti-infective and anticancer product category, particularly the INTRON franchise (INTRON A, PEG-INTRON, and REBETOL). Sales for this franchise increased by 90% year-to-date due to the successful launch of PEG-INTRON combination therapy for hepatitis C.

What are the main concerns regarding CLARITIN sales?

CLARITIN sales are facing pressure from both patient conversion to the newer drug CLARINEX and, more significantly, the impending threat of generic competition. The compound patent for loratadine expired on June 19, 2002, and market exclusivity extends only to December 19, 2002. A recent court ruling has weakened patent protection for a 2004 patent, potentially allowing generic versions to enter the market as early as December 20, 2002, which is expected to cause a rapid and sharp decline in CLARITIN sales.

What is the financial impact of the FDA consent decree?

The company has agreed to pay $500 million to the U.S. government under the terms of the consent decree related to Good Manufacturing Practices. The first installment of $250 million was paid in May 2002, with the second installment due in the second quarter of 2003. A provision for this amount was already accrued in the fourth quarter of 2001. Failure to meet the decree's terms could result in additional daily payments or royalties.

How is the company's financial health perceived by rating agencies?

Standard & Poor's lowered Schering-Plough's long-term credit rating from 'AA' to 'AA-' on July 25, 2002, while maintaining a negative outlook. The short-term credit rating of 'A-1+' was reaffirmed.

MRK 10-Q Quarterly Report Q2 FY2002 — Revenue, Net Income, EPS

Summary

Schering-Plough Corporation reported solid revenue growth for the six months ended June 30, 2002, with consolidated net sales increasing by 9% to $5.39 billion. This growth was primarily driven by strong performance in the anti-infective and anticancer categories, notably the INTRON franchise, which saw a 90% surge in sales. International sales also showed significant strength, growing 15% year-to-date. Diluted earnings per share remained stable at $0.43 for the quarter, and increased by 4% to $0.84 for the six-month period compared to the prior year. Despite the positive revenue trend, the company faces significant headwinds. The CLARITIN franchise, a major revenue driver, experienced an 8% decline in sales for the quarter and a 12% decline year-to-date, impacted by the conversion to CLARINEX and increasing generic competition. Furthermore, the company is dealing with the implications of a recently approved FDA consent decree related to Good Manufacturing Practices, which includes a $500 million payment to the U.S. government. The potential introduction of generic loratadine by December 20, 2002, poses a material risk to CLARITIN and CLARINEX sales, with management anticipating a rapid and sharp decline. Investors should closely monitor the ongoing patent litigation surrounding CLARITIN and the regulatory landscape.

Key Highlights

1Consolidated net sales increased by 9% to $5.39 billion for the six months ended June 30, 2002, compared to the same period in 2001.
2The INTRON franchise (INTRON A, PEG-INTRON, REBETOL) demonstrated exceptional growth, with sales up 90% year-to-date, driven by the launch of PEG-INTRON combination therapy for hepatitis C.
3Allergy & Respiratory product sales decreased by 8% in the quarter and were flat year-to-date, primarily due to a 14% decline in CLARITIN family sales and patient conversion to CLARINEX.
4The company reached an agreement for an FDA consent decree, involving a $500 million payment to the U.S. government, to resolve Good Manufacturing Practices issues.
5Generic competition for CLARITIN is a significant concern, with potential market entry as early as December 20, 2002, which could materially impact future sales.
6Diluted earnings per share were $0.43 for the quarter, flat year-over-year, and increased 4% to $0.84 for the six-month period.
7Standard & Poor's lowered the company's long-term credit rating to 'AA-' with a negative outlook.

Merck & Co., Inc. Quarterly Report for Q2 Ended Jun 30, 2002

Summary

Key Highlights

Frequently Asked Questions